Product Information
PIFELTRO 100 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $60.7869 per EA under NDC 00006306901. Its NADAC has been published 363 times since Oct 23, 2019.
FDA first approved this application on Aug 30, 2018.
Strength
100 mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006306901
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DORAVIRINEApproval Type
New Drug (NDA)
FDA Application
NDA210806FDA Approved
8/30/2018
On Market Since
7/20/2018
Pharmacological Classes
Price Statistics
The NADAC for PIFELTRO 100 MG TABLET has been published 363 times since Oct 23, 2019, and over the history we have for it it has risen 36.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $60.7869 per EA |
|---|---|
| All-time high | $60.9498 (May 13, 2026) |
| All-time low | $44.3183 (Nov 20, 2019) |
| 52-week high | $60.9498 |
| 52-week low | $59.3904 |
| Median price | $54.3347 |
| Average price | $53.5842 |
| Largest weekly change | +5.0% (Jan 15, 2020) |
| Weeks tracked | 363 |
| Tracking since | Oct 23, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doravirine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doravirine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIFELTRO 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PIFELTRO 100 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $60.7869 per EA (NDC 00006306901), effective Sep 30, 2026.
How has the price of PIFELTRO 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for PIFELTRO 100 MG TABLET has risen 36.1%. It has been tracked across 363 weekly CMS publications since Oct 23, 2019.
What are the highest and lowest recorded NADAC prices for PIFELTRO 100 MG TABLET?
Since Oct 23, 2019, the NADAC for PIFELTRO 100 MG TABLET has ranged from a low of $44.3183 (Nov 20, 2019) to a high of $60.9498 (May 13, 2026), with a median of $54.3347 per EA.
Are there cheaper alternatives to PIFELTRO 100 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PIFELTRO 100 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PIFELTRO 100 MG TABLET?
PIFELTRO 100 MG TABLET (NDC 00006306901) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.